Xizang Weixinkang Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 219 million yuan, a year-on-year decrease of 9.9%Zhitong·Oct 29, 2025 at 09:22 AM603676-3.01%
Xizang Weixinkang Pharmaceutical: Net profit of 183 million yuan in the first half of 2025, a year-on-year increase of 11.82%Zhitong·Aug 27, 2025 at 04:31 AM603676-3.01%
Pharmaceutical stocks continue to be strong, FUSHILAI hits the 20% limit up, Tuoxin Pharmaceutical and Cosunter rise over 10%, Xizang Weixinkang Pharmaceutical, MEDISAN and several other stocks hit the limit upZhitong·Jul 7, 2025 at 08:48 PM301258-1.93%301089-6.02%
Xizang Weixinkang Pharmaceutical: Received government subsidies related to revenue amounting to 34.3437 million yuanZhitong·Jun 30, 2025 at 06:38 AM603676-3.01%
Xizang Weixinkang Pharmaceutical: Cooperative product injectable multivitamins (12) passed the consistency evaluation of generic drugsZhitong·Jun 24, 2025 at 03:38 AM603676-3.01%
Xizang Weixinkang Pharmaceutical's subsidiary withdraws the registration application for Pediatric Compound Amino Acid Injection (20AA)Zhitong·May 9, 2025 at 02:57 AM603676-3.01%
Xizang Weixinkang Pharmaceutical's subsidiary has received the clinical trial approval notice for the drugZhitong·May 7, 2025 at 04:22 AM603676-3.01%
Xizang Weixinkang Pharmaceutical: Elected Daniel Zhang as ChairmanZhitong·Apr 30, 2025 at 08:04 AM603676-3.01%
Xizang Weixinkang Pharmaceutical: Subsidiary Compound Amino Acid Injection Obtains Drug Registration CertificateZhitong·Apr 27, 2025 at 04:07 AM603676-3.01%
Xizang Weixinkang Pharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 84.54 million yuan, a year-on-year decrease of 10.93%Zhitong·Apr 25, 2025 at 10:04 AM603676-3.01%
Xizang Weixinkang Pharmaceutical: The company does not have any significant matters that should be disclosed but have not been disclosed regarding the planning involving the companyZhitong·Apr 24, 2025 at 03:35 AM603676-3.01%
Xizang Weixinkang Pharmaceutical: Subsidiary's drugs pass the consistency evaluation of generic drugsZhitong·Apr 22, 2025 at 03:04 AM603676-3.01%
The biopharmaceutical sector continued to rise in the afternoon, with FUSHILAI hitting the daily limitZhitong·Apr 22, 2025 at 12:39 AM600276-3.56%002675-2.61%
Xizang Weixinkang Pharmaceutical's subsidiary, Amber Acetylated Gelatin Electrolyte Sodium Acetate Injection, has been approved for clinical trialsZhitong·Apr 16, 2025 at 02:35 AM603676-3.01%
Xizang Weixinkang Pharmaceutical: Clinical trial approval for Ketoprofen patch medicationZhitong·Mar 25, 2025 at 04:06 AM603676-3.01%
